The FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
